Sunday, July 20, 2025 6:51 AM

Tag: Nuvalent

Nuvalent, Inc. ($NUVL) advances front-line strategies for ROS1 and ALK-positive NSCLC programs

Staff Writer -
Nuvalent, Inc. (NUVL) announced positive pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer...
Our platform offers actionable news and data on events that could sway financial markets. At Catalyst DAILY, we monitor a wide variety of market catalysts, which are essential events or announcements that can trigger significant price movements in stocks, currencies, or entire sectors.

OUR WEBSITE STRICTLY PROHIBITS ANY FORM OF PROMOTION OR TOUTING
Contact us: info@catalystdaily.com
© Catalyst Daily 2025